Krystal Biotech discloses single-patient data from discontinued KB801 study in patent response

Krystal Biotech, Inc.

Filed response to USPTO Office Action for KB801 patent application; included data from one patient in discontinued clinical study.
Patient experienced complete closure of persistent corneal epithelial defect after KB801 treatment.
Study discontinued to advance KB801 into pivotal trial; no safety concerns or serious adverse events observed.
Company cautions that single-patient observation is not top-line results and no conclusions on safety/efficacy should be drawn.
Pivotal trial results for KB801 expected to be reported in ordinary course.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.